Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial

scientific article published on 01 January 1991

Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID1984797

P2093author name stringvan Marwijk Kooy M
Akkerman JW
Moes M
van Prooijen HC
Bosma-Stants I
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectrandomized experimentQ1231081
P304page(s)201-205
P577publication date1991-01-01
P1433published inBloodQ885070
P1476titleUse of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial
P2283usesrandomized experimentQ1231081
P478volume77

Reverse relations

cites work (P2860)
Q24186913A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q90708330Analysis of Plasma Products for Cellular Contaminants: Comparing Standard Preparation Methods
Q71787415Autologous platelet transfusion in alloimmunized patients with acute leukemia
Q46689029C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Q42147720Comparative Study of Predeposit and Bedside Leucodepletion Filters
Q24187751Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q33412070Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets
Q24186359Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q33432719Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions
Q35924467Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products
Q26771857Leucoreduction of blood components: an effective way to increase blood safety?
Q33760699Leukoreduced blood components: Advantages and strategies for its implementation in developing countries
Q37303143Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response
Q30539028Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants
Q28749508Management of allosensitized cardiac transplant candidates
Q90627632Pathogen reduction with riboflavin and ultraviolet light induces a quasi-apoptotic state in blood leukocytes
Q33345178Platelet therapy
Q34708937Platelet transfusions: Impact on hemostasis, thrombosis, inflammation and clinical outcomes
Q38794017Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.
Q36746594The HLA system: genetics, immunology, clinical testing, and clinical implications
Q36766478The Use of Splenectomy to Manage Platelet Transfusion Refractoriness due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation
Q41979922Time Dependent Release of Interleukin-8 and Tumor Necrosis Factor-α in Platelet Concentrate

Search more.